Introduction
Her-2/neu is one of the tumor-associated antigens that are overexpressed in human carcinomas such as breast and ovarian cancer. 1, 2 This overexpression is known to be correlated with malignancy and with a poor prognosis for patients with Her-2/neu-expressing tumors. 3 Previously, we have shown that immunization with genetic or cell-based vaccines targeting human Her-2/neu efficiently generated human Her-2/neu-specific immune responses in a murine model. [4] [5] [6] However, because Her-2/neu is a foreign antigen that is highly immunogenic in mice, the immunogenicity of the vaccine tested in a murine model may not represent its efficacy in humans. Immune responses against self-tumor antigens like Her-2/neu are under the control of self-tolerance mechanisms. 2, 7 In this regard, we have shown that adenoviral vaccine expressing human Her-2/neu could elicit antitumor immunity against murine Her-2/neu-expressing tumors by breaking immunologic tolerance once the tumor-driven immunosuppressive environment was attenuated by the appropriate chemotherapy. 7 Before evaluating the antitumor efficacy of genetic vaccines in combination with chemotherapy in human clinical trials, we need to assess whether our genetic vaccine can elicit Her-2/neu-specific immune responses in humans. Because 98% of the amino-acid sequences of Her-2/neu are shared in humans and rhesus monkeys (Macaca mulatta), the immunogenicity of genetic vaccines in monkeys may prove useful for predicting the potential of the vaccine in humans. Further, safety profiles developed in a simian model will provide more credible preclinical data than those developed in a murine model.
To assess the efficacy and safety of anti-Her-2/neu genetic vaccines in large animals, we immunized monkeys with a DNA vaccine and/or adenovirus vaccine. We used human granulocyte-macrophage colony-stimulating factor (GM-CSF) as a genetic adjuvant for the DNA vaccine to enhance immune responses against Her-2/neu. On the basis of previous reports of the limited efficacy of DNA vaccines in patients, 8, 9 we combined adenoviral vaccine with DNA immunization to increase the immunogenicity of the DNA vaccine. The preclinical data obtained from our study suggest that Her-2/neu genetic vaccines might be both immunogenic and safe in humans.
Results

Construction of genetic vaccines expressing human Her-2/neu
We previously reported that immunization of mice with pHM-GM-CSF that expressed truncated hHer-2/neu and murine GM-CSF effectively generated protective and therapeutic antitumor immunity by inducing Her-2/neuspecific antibodies and cytotoxic T cells. 4 We constructed a plasmid DNA, pCK-HM-IRES-hGM-CSF (pHM-hGM-CSF), in which a truncated form of human Her-2 and human GM-CSF had been encoded independently, for the application of genetic adjuvant GM-CSF in the preclinical study using nonhuman primates.
Although the DNA vaccine has been thought to offer considerable promise in anticancer immunotherapy, the outcomes of recent clinical studies fell short of expectations. 8, 9 Thus, to boost DNA-primed Her-2/neu-specific immune responses, we also constructed an adenoviral vaccine expressing the extracellular and transmembrane domain of human Her-2/neu using nonreplicating adenovirus vector. The expression of Her-2/neu and/or hGM-CSF by the genetic vaccine constructs was confirmed by fluorescence-activated cell sorting (FACS) and immunoblot analysis after in vitro transduction of CT26 or 293T cells with pHM-hGM-CSF or AdHM (Figure 1 ).
Immunization schema of cynomolgus monkeys
Nine monkeys were randomly divided into three groups (three monkeys per group). Monkeys in group 1 were injected with saline instead of pHM-hGM-CSF or AdHM immunization as delineated in Supplementary Table 1 . Monkeys in group 2 were primed with AdHM alone on week 3 and boosted with three weekly intramuscular (i.m.) injections of pHM-hGM-CSF on weeks 14, 15 and 16. Finally, monkeys in group 3 were primed with three weekly i.m. injections (4 mg per vaccination) of pHMhGM-CSF on weeks 0, 1 and 2, followed by a single i.m. injection of AdHM (10 10 plaque-forming units (PFUs) per vaccination) on week 3. These three monkeys, like those in group 2, were boosted on weeks 14, 15 and 16 with pHM-hGM-CSF.
Genetic immunization of monkeys generated Her-2/neu-specific humoral immune responses
To determine whether the immunization of cynomolgus monkeys with the constructed vaccines could establish humoral immune responses specific to Her-2/neu, we measured the titers of Her-2/neu-specific antibodies in sera from immunized monkeys using an SK-BR-3 cellbinding assay. The titers of sera from immunized monkeys were determined by a two-fold increase in mean fluorescence intensity (MFI) of SK-BR-3 binding over that of respective preimmune sera (Figure 2a ). When tested with sera from the monkeys in group 2, AdHM immunization increased the titers of sera from immunized monkeys to 12 800 within 4 weeks. Although we could not detect Her-2-specific binding in sera from monkeys immunized with pHM-hGM-CSF until week 3, a boosting immunization of DNA-primed monkeys with AdHM more rapidly increased the titers than did AdHM alone (100 ± 50 vs 700 ± 458). However, we could not detect any further increase in Her-2-specific antibody (Ab) titers when the monkeys in groups 2 and 3 were boosted with pHM-hGM-CSF on weeks 14, 15 and 16. The overall Ab production generated by the genetic vaccine persisted at least 18 weeks. In contrast, we could not observe any Her-2/neu-specific binding in sera from saline-treated monkeys in group 1.
We next tested for antibodies that could share the epitope specificity with Herceptin, the widely used monoclonal antibody to treat Her-2/neu-positive human carcinoma. When the sera from the immunized monkeys were tested in sandwich enzyme-linked immunosorbent assay (ELISA) using Her2/ECD fusion protein, Herceptin binding was specifically inhibited by the sera from monkeys immunized with Her-2-expressing genetic vaccines (Figure 2b) .
Because the antitumor effect of several antibodies was partially dependent on antibody-dependent cellmediated cytotoxicity (ADCC) as well as direct binding with tumor antigen on the cell surface, we tested antibody-dependent killing of SK-BR-3 cells of sera using human peripheral blood mononuclear cells (PBMCs) as effectors. Immunization of monkeys with either AdHM alone or AdHM with pHM-hGM-CSF could induce antibodies capable of participating in ADCC; no Non-human primate study against human Her-2/neu H-J Ko et al significant difference was observed between groups 2 and 3 ( Figure 2c ). However, sera from saline-injected monkeys did not induce specific lysis of target cells. These data show that our genetic vaccines can efficiently induce Her-2-specific humoral immune responses persisting for at least 18 weeks and ADCC.
Construction of B lymphoblastoid cell lines and BLCL-HM
Because stably transduced B lymphoblastoid cell lines (BLCLs) expressing specific tumor antigen are useful antigen-presenting cells (APCs) that can efficiently stimulate CD4 + and CD8 + T cells as well as act as cytotoxic T-lymphocyte (CTL) targets, we generated simian BLCL by infecting PBMC with Herpesvirus papio. BLCL-HM that stably expressed Her-2/neu on the cell surface was constructed by transfecting BLCL with retrovirus expressing human Her-2/neu. The expression of CD20 and major histocompatibility complex (MHC) class I on the BLCL and BLCL-HM was assessed to confirm the phenotype of BLCL (Supplementary Figure   1) . Although the expression level of Her-2/neu differed slightly among monkeys, BLCL-HM was found to stably express significant levels of Her-2/neu on the cell surface (Supplementary Figure 1) .
Her-2-specific lymphoproliferative capacity of splenocytes was significantly increased by genetic immunization
To test whether the splenocytes obtained from immunized monkeys were responsive against Her-2/neuspecific restimulation, we co-incubated splenocytes from groups of monkeys with the respective mitomycin C (MMC)-treated BLCL or BLCL-HM for 96 h, including a final 24-h pulse with [ 3 H]thymidine. Proliferation in BLCL-HM-stimulated splenocytes was twice than that observed with BLCL stimulation in all three monkeys in group 2 ( Figure 3 ). Although one of the three monkeys in group 3 (monkey no. 7) showed a profound increase in Her-2-specific proliferation in splenocytes after stimulation with BLCL-HM vs BLCL, the same level of proliferation was attained in the other two monkeys The Herceptin-binding inhibition assay was conducted. Her2/ECD-coated plates were incubated with 6.25 ng ml À1 of biotin-labeled Herceptin and diluted sera. The percentage of inhibition was calculated as (6.25À Herceptin equivalent/6.25) Â 100. (c) The antibody-dependent killing of Her-2/neu-expressing cells was measured using sera of immunized monkeys obtained at week 20 after immunization using human peripheral blood mononuclear cells (PBMCs) as effectors. Cr-51-labeled SK-BR-3 was incubated with diluted sera for 15 min before the addition of human PBMCs. After 4 h, Her-2/neu-specific lysis was measured by detecting Cr-51 release in the supernatant. As a positive control, antibody-dependent cell-mediated cytotoxicity (ADCC) of diluted Herceptin (200 ng ml À1 ) was assessed.
Non-human primate study against human Her-2/neu H-J Ko et al (monkey nos. 8 and 9) by BLCL stimulation alone. However, we could not detect significant levels of Her-2-specific proliferation in any of the saline-treated monkeys in group 1. These data show that our genetic vaccines elicited priming of Her-2-specific T cells in the spleen of immunized monkeys. These Her-2-specific cells in the spleen, which can function after recognition of antigen in vitro, persisted for at least 10 weeks after the final immunization.
Her-2-specific IFN-g secretion occurred during in vitro culture of splenocytes from immunized monkeys
We tested whether the in vitro incubation of splenocytes from immunized monkeys with MMC-treated BLCL-HM induced Her-2-specific interferon-g (IFN-g) secretion after 10 days of culture. When the culture supernatants of splenocytes were assessed using ELISA, most restimulated splenocytes from groups 2 and 3 monkeys secreted considerable Her-2-specific IFN-g (41000 U ml À1 ); IFN-g secretion after Her-2-specific restimulation was not detected in only one monkey (monkey no. 9) in group 3. However, no difference was observed in IFN-g secretion between monkeys in groups 2 and 3 ( Figure 4 ). In contrast, restimulation with BLCL-HM or BLCL did not result in significant IFN-g secretion by splenocytes in group 1 monkeys. These results suggest that our vaccine strategy elicited effective memory-type splenocytes that secreted IFN-g when restimulated by Her-2-expressing BLCL.
Her-2-specific cytotoxic T-lymphocyte activities of splenocytes were significantly increased by genetic immunization
Using an in vitro CTL assay, we next assessed the Her-2-specific cytolytic activities of splenocytes from immunized monkeys. After incubation of splenocytes with MMC-treated BLCL-HM, Her-2-specific lysis of BLCL-HM cells was measured by a standard Cr-51 release assay. Because long-term in vitro culture of splenocytes with BLCL-HM may induce primary CTL responses against BLCL as well as restimulation of preestablished Her-2-specific memory CD8
+ T cells, we added only 1 U ml À1 of interleukin-2 (IL-2) once on day 8 and then used the in vitro CTL assay to evaluate restimulated CTL activity on day 10. Splenocytes from three monkeys in group 3, which were primed with pHM-hGM-CSF and AdHM followed by pHM-hGM-CSF boosting, efficiently lysed BLCL-HM, but not BLCL (Figure 5a ). Although splenocytes from two group 2 monkeys (monkeys no. 4 and 5) that had been primed with AdHM and boosted with pHM-hGM-CSF showed enhanced specific lysis of BLCL-HM, they could also lyse BLCL to the levels of BLCL-HM lysis after 10 days of in vitro stimulation with MMC-treated BLCL-HM. Thus, the splenocytes from monkeys in group 2 were further incubated with BLCL-HM for 14 days and supplemented with 1 U ml À1 of IL-2 on day 8 and day 10. After prolonged incubation of splenocytes from monkeys in group 2, Her-2-specific lysis of BLCL-HM was slightly greater than that of BLCL, especially in monkeys no. 4 and 5 ( Figure 5b ). However, we could detect no Her-2-specific cytolytic activity of splenocytes in monkey no. 6 even after prolonged incubation with BLCL-HM. In contrast, splenocytes from saline-treated monkeys in group 1 did not lyse either BLCL or BLCL-HM (Figure 5a ). These results show that genetic vaccines using AdHM and pHM-hGM-CSF efficiently elicited CTL responses after Her-2-specific in vitro restimulation.
Safety evaluation of genetic vaccines in cynomolgus monkeys
Our evaluation of the toxicities of genetic vaccines using our immunization schema revealed no statistically significant differences in weight loss, unconsumed feed, diarrhea or death in treated monkeys (data not shown). We monitored immunized monkeys for 22 weeks for odd ophthalmological findings and abnormalities in hepatic and renal chemistry and serum biochemistry (Supplementary Table 2 ). Because there might be acute inflammation-mediated toxicity after genetic vaccination, we also checked the level of inflammatory cytokines in the sera of immunized monkeys on weeks 0, 3, 4, 13, 17 and 21 after immunization, showing no significant increase in the level of serum IL-6 and tumor necrosis factor-a (TNF-a) after immunization (Supplementary Figure 2) . To investigate vaccination-related effects on organs, monkeys were killed on week 22 and autopsies were performed. A total of 41 organs were isolated, weighed and examined grossly and histopathologically. Treatment-related abnormalities were not observed in any organs including liver and heart (data not shown). These findings led us to conclude that our genetic vaccines efficiently elicited Her-2-specific immune responses without causing immunization-related adverse effects in nonhuman primates.
Discussion
Her-2/neu has been of keen interest as a target for cancer immunotherapy for decades. Indeed, passive immunotherapies using Her-2/neu-specific Ab or T cells have been partially successful in combating Her-2/neu-expressing cancer as a second-line therapy for chemotherapy and surgery. [10] [11] [12] Furthermore, several APC-based vaccines loaded with Her-2/neu antigenic peptide or Her-2/neu peptide-based vaccine alone could induce Her-2/neu-specific immune responses in cancer patients. 13, 14 However, few studies have dealt with the immunogenicity and safety of Her-2/neu genetic vaccines in cancer patients or even in nonhuman primates, despite the abundance of data in rodent models. 4, [15] [16] [17] Genetic vaccines have been developed rely on the expression of antigen inside of cells by naked plasmid DNA or viral vectors after gene delivery into the immunized; these vaccines can elicit both humoral and cellular immune responses against expressed antigen.
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Although we previously used a DNA vaccine expressing a truncated form of Her-2/neu to generate successful antitumor immunity against Her-2/neu-expressing tumor cells in a mouse model by eliciting human Her-2/ neu-specific humoral and cellular immune responses, 4, 6 this approach may not be equally suitable in overcoming self-tolerance and inducing effective immune responses in humans. Thus, to properly examine the efficacy of genetic vaccines prior to clinical trials, the immunogenicity and the safety of the vaccines need to be tested in large animals such as nonhuman primates. 19 In the current study, we have evaluated the immunogenicity and the safety of genetic vaccine approaches in nonhuman primates, establishing the basis for the clinical use of the Her-2/neu genetic vaccines.
Genetic vaccines including plasmid DNA vaccines made it possible to elicit effective immune responses against many antigens. 20 It was shown that DNA vaccine against prostate-specific antigen (PSA) induced PSAspecific Ab production and lymphoproliferative responses in immunized macaques; the stimulated T cells from PSA-immunized rhesus macaques produced high levels of Th1 cytokine IFN-g, but not of IL-4, without any adverse effects. 21 Likewise, the i.m. administration of DNA vaccine against carcinoembryonic antigen (CEA) was reported to produce comparable immune responses in immunized monkeys. 22 However, human clinical trials of CEA DNA vaccine elicited only low levels of lymphoproliferative responses and could not induce humoral immune responses to CEA after vaccination. Figure 4 Her-2/neu-specific interferon-g (IFN-g) secretion occurred during in vitro culture of splenocytes from immunized monkeys. In total 5 Â 10 6 cells of splenocytes and 2.5 Â 10 5 cells of mitomycin C (MMC)-treated stimulator cells were co-incubated in 1 ml of culture media for 10 days; 1 U ml À1 of human interleukin-2 (IL-2) was added at day 8. The concentrations of simian IFN-g in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). The negative optical density (OD) values were expressed as under the detection limit (o10 U ml
À1
). The data shown are representative of two separate experiments.
Non-human primate study against human Her-2/neu H-J Ko et al Further, DNA vaccine alone could not generate detectable levels of immune responses in melanoma patients. 9 To increase the limited immunogenicity of plasmid DNA vaccines, several investigators have used recombinant viruses as a boost for DNA vaccines. 23 Although adenoviruses are widely used as vectors in clinical gene therapy trials, their use was limited because they induced adenovirus-specific innate and adaptive immune responses 24 that could be detrimental to the generation of tumor antigen-specific immune responses. 9 To reduce these adenovirus-specific responses, we designed prior immunizations with plasmid DNA vaccine. Subsequent DNA vaccination can also boost antigen-specific memory responses induced by DNA and/or adenovirus immunization. Therefore, we combined plasmid DNA and adenovirus to maintain prolonged antigen-specific immune responses in immunized hosts. Further, intravenous injection of adenovirus vector has been reported to cause liver toxicity, because most of the intravenously administered adenovirus vectors were taken up by Kupffer cells in the liver, causing hepatotoxicity associated with the production of proinflammatory cytokines such as IL-6, TNF-a and RANTES. 25 However, in active immunotherapy, activated innate immunity may contribute to the generation of robust immune responses against delivered gene product. In the current nonhuman primate study, i.m. Non-human primate study against human Her-2/neu H-J Ko et al detectable levels of acute toxicity, including liver and cardiac toxicities.
With our genetic vaccines, we could elicit high levels of Her-2-specific antibodies capable of lysing Her-2/neuexpressing tumor cells via ADCC. Further, some of these antibodies could compete with Herceptin in the binding inhibition assay (Figure 1c) , leading us to conjecture that our Her-2/neu genetic vaccines may generate Her-2-specific antibodies that share epitope specificity with Herceptin even in clinical trials. Although DNA vaccine alone could not elicit Her-2-specific Ab responses within 4 weeks after initial immunization, we could detect rapid increases in Ab titers following immunization with AdHM. In contrast, Her-2-specific Ab production was evoked within a week after administration with AdHM alone and plateaued in 4 weeks. Because the Ab responses elicited by genetic vaccines persist for at least 18 weeks, we could not observe the effect of DNA boosting in our schema.
Although preimmunization with pHM-hGM-CSF followed by immunization with AdHM did not dramatically affect humoral immune responses, it led to striking differences in cellular immune responses. Immunization with AdHM alone remarkably increased Her-2-specific helper T-cell responses, including the proliferation of splenocytes after Her-2-specific restimulation and their secretion of IFN-g. However, Her-2/neu nonspecific proliferation was increased by the pHM-hGM-CSF immunization given before AdHM immunization in two of three monkeys in group 3, perhaps because of the strong immunostimulatory effect of consecutive immunization with DNA and adenoviral vaccines during the priming. In contrast, distinct Her-2-specific CTL activities were observed mainly in splenocytes of monkeys in group 3 that were given pHM-hGM-CSF together with AdHM, whereas priming with AdHM immunization alone increased Her-2-specific target lysis only slightly more than nonspecific lyses of BLCL, which were a bit higher than those in group 3. Because we tested the cellular immune responses using splenocytes harvested at the end time point of the study, we could not conclude which of the vaccination regimens most effectively generated antitumor immunity at the immune induction phase. However, because Her-2 genetic vaccines elicited considerable levels of humoral immune responses in all monkeys to which they were administered, we can presume that various levels of Her-2-specific cellular immune responses may also be generated in immunized monkeys. Actually, in the case of monkey no. 9, we observed no Her-2-specific CTL and IFN-g secretion of splenocytes despite Her-2-specific lymphoproliferative responses and Ab production. Because every monkey used in this study has different genetic background like in cases of human patients, the different levels of Her-2 expression, MHC-heterogeneities as well as Her-2 polymorphism among monkeys could influence on the T-cell repertoires by affecting T cell-positive and -negative selection process in thymus.
Mounting evidence suggests that CD8 + T cell responses, particularly CTL activity, play a critical role in controlling tumor eradication in tumor-bearing mice models and cancer patients. 26, 27 Several vaccine strategies using HLA-A2-binding Her-2/neu CTL epitope peptide were reported to be safe and effective in eliciting CTL responses even in Her-2/neu-expressing cancer patients. 28, 29 However, it is difficult to directly measure CTL activity in nonhuman primates, because little information is available on MHC class I-binding epitope peptide. Thus, as an alternative, autologous BLCLs transduced with retroviral vector-expressing antigen have been used as stimulator and target cells. 30, 31 In the current study, we have evaluated the cytolytic activity of CD8 + T cells in the splenocytes of immunized monkeys, finding that stimulation with BLCL transduced with Her-2-expressing retroviral vector efficiently initiated CTL activity for the killing of Her-2/neu-expressing target cells.
GM-CSF, one of the most widely studied genetic adjuvants, has a good track record of enhancing antitumor immunity. 32, 33 Although immunization with engineered tumor cells secreting low levels of GM-CSF generated measurable increases in antitumor effect, highdose expression of GM-CSF instead impaired the immune responses by inducing the recruitment of myeloid-derived suppressor cells. 34 GM-CSF may also promote tumor cell transmigration through the endothelial barrier 35 and high levels of GM-CSF secreted by cancer cells were shown to promote osteolytic bone metastasis. 36 Likewise, in clinical trials of GM-CSF-based vaccine, some patients with metastatic melanoma showed rapid disease progression. 37 In the current study, i.m. administration of pHM-hGM-CSF led to only low levels of local GM-CSF secretion (Figure 1b) , which only last for 14 days (data not shown). Recently, however, low dose GM-CSF treatment also has been shown to expand CD14 + HLA-DR À/lo cells, which have features of myeloid suppressor cells, in melanoma patients. 38 Thus, although most GM-CSF-related adverse effects seemed to stem from high-dose secretion of GM-CSF, our strategy using GM-CSF as genetic adjuvant should carefully be monitored in clinical trials.
The primary safety concern of a clinical Her-2-based vaccine is the development of cardiotoxicity that is the dominant clinical toxicity might be induced by Herceptin administration after chemotherapy. 39 Although Herceptin-like antibodies were generated by our Her-2/neu vaccines, there was neither inflammatory process nor cardiac dysfunction in all of the immunized monkeys. It might be due to relatively low titers of the specific antibodies or due to the discrepancy in amino-acid sequences between humans and monkeys. However, as we obtained data from the limited numbers of monkeys, further investigations should be made to verify the risk of anti-Her-2/neu-specific antibodies related cardiotoxicity by Her-2-based vaccines.
Although many of the genetic vaccines that have been tested to date were found to be safe and well tolerated, no good correlation has been established between positive lymphoproliferation and stable diseases. 8, 19, 22 To assess the immunogenicity of our vaccines in clinical trial, we tested the efficacy and the safety of these vaccines in nonhuman primates. Our genetic vaccines provided a clear advantage over passive Ab therapy; namely, they efficiently and simultaneously elicited humoral and cellular immune responses, including CTL activity as well as lymphoproliferation and IFN-g secretion after Her-2-specific restimulation. Further, because some chemotherapies, especially gemcitabine or cyclophosphamide treatment, can attenuate the tumor-suppressive environment by eliminating myeNon-human primate study against human Her-2/neu H-J Ko et al loid-derived suppressor cells 7 or tumor-induced regulatory T cells, 40 in addition to directly killing tumor cells via their the intrinsic anti-neoplastic nature, genetic vaccines can be administered after chemotheraphy for the treatment of human cancer. In this regard, our vaccine might be used to develop both a therapeutic vaccine for reducing metastasis after chemotherapy and a prophylactic vaccine for people from genetically highrisk populations. For immunization, groups of monkey (three monkeys per group) were i.m. injected with 2 ml of pHM-hGM-CSF plasmid DNA (2 mg ml
Materials and methods
Animals
À1
) and 1 ml of AdHM (1 Â 10 10 PFUs per ml) (Supplementary Table 1 ). Blood samples were taken from the cephalic vein using a CTP cell preparation tube (BD Biosciences, Franklin Lakes, NJ, USA) with sodium citrate to isolate PBMC and a vacuette (BD Biosciences) with heparin to obtain sera. Monkeys were killed on week 22 for the toxicity test and a part of the spleen was removed to obtain splenocytes. Splenocytes were frozen after red blood cell lysis.
Cell line
The Her-2/neu-expressing human breast carcinoma SK-BR-3 cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). Her-2/neuexpressing transfectoma Her-2/CT26 cells were developed by transduction of CT26 cells with the cDNAencoding human Her-2/neu. 4 
Construction of vaccines
The plasmid pHM, which encodes the extracellular domain and transmembrane domain of Her-2/neu without the intracellular domain of Her-2/neu was previously described. 4, 6 HM-encoding recombinant adenovirus (AdHM) was constructed using the adenovirus genomic DNA-TPC co-transfection method outlined by the manufacturer (TaKaRa Bio, Japan) and as previously described. 41 
FACS and immunoblot
pHM-hGM-CSF (2 mg) were transfected with 293T cells using CellPhect Transfection Kit (Amersham, Little Chalfont, Buckinghamshire, UK). Two days after transfection, the culture supernatant of 293T cells was obtained, filtered with 0.2-mm membrane filter, and used for ELISA. The level of hGM-CSF was determined using an ELISA kit (Endogen, Rockford, IL, USA) according to the manufacturer's manual. The harvested 293T cells were analyzed by FACS (BD Biosciences) or immunoblot for the cell-surface expression of Her-2/neu as previously described. 4 To detect the expression of HM produced from AdHM, CT26 cells were transduced with AdHM at 100 multiplicities of infection (MOI). Two days after transduction, the cells were harvested and the level of HM expression was analyzed using FACS or immunoblot as described above.
Sera from immunized monkeys were screened by FACS for Her-2/neu-specific antibodies. SK-BR-3 cells were incubated with serially diluted sera for 1 h at 4 1C, with free sera washed away. After washing, SK-BR-3 cells were incubated with goat anti-monkey immunoglobulin G-FITC (Serotec, Oxford, UK) for 40 min at 4 1C. After incubation, free antibodies were washed away and Her-2/neu-specific antibodies were measured by FACS calibur (BD Biosciences). Antibody levels were determined by end point titration titer.
Antibody-dependent cell-mediated cytotoxicity
The SK-BR-3 cells were incubated with 200 mCi ml À1 of Na[
51 Cr]O 4 (Dupont NEN, Boston, MA, USA) at 37 1C for 1.5 h. At the end point of the labeling period, the labeled target cells were washed three times in RPMI 1640 medium and plated in a 96-well round-bottom microplate at a concentration of 10 4 cells per well. Target cells were incubated for 15 min at 37 1C in 5% CO 2 in the presence of diluted sera from immunized monkeys, which were preincubated for 30 min at 56 1C to inactivate complement, and then for another 4 h after human PBMC was added as effector (effector:target ¼ 40:1). After incubation, the plate was centrifuged and the 51 Cr radioactivity in supernatants was determined in a Wallac 1470 Wizard automatic gamma counter. The percentage of specific lysis was calculated as ((experimental releaseÀbackground release)/(maximal releaseÀbackground release)) Â 100. Background release was defined as 51 Cr release by targets in the absence of specific antibodies, and the maximal release was determined after lysing target cells with 0.5% Triton X-100. The means of triplicate determinations are given.
Inhibition assay
A previously established sandwich-ELISA was modified for the inhibition assay. 42 In brief, multiwell plates (Nunc, Denmark) were coated with 2 mg ml À1 of antiHis6 Ab (Igtherapy, Korea) diluted in 50 mM NaHCO 3 (pH 9.6) overnight at 4 1C. After blocking and washing, 200 ng ml À1 of Her2/ECD (R&D systems, Minneapolis, MN, USA) was added and incubated at room temperature for 4 h. Plates were washed, and serially diluted monkey sera were added to the wells. After a 30-min incubation, biotin-labeled Herceptin (Roche, California, CA, USA) was added without washing to attain a final concentration of 6.25 ng ml
À1
. Plates were incubated for 1.5 h at room temperature. After washing, plates were incubated with Streptavidin-horseradish peroxidase (Sigma, St Louis, MO, USA) for 30 min and developed with 100 ml of TMB (Moss Inc., Pasadena, MD, USA). After 30 min, 50 ml of 0.5 N HCl was added to stop development, and optical density (OD) was detected at 450 nm.
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